Valeur202020212022202320242025TTMFlux de trésorerie liés aux activités d'investissement-435.52 M-273.3 M169.35 M-336.35 M-116.84 M436.33 M348.1 MFlux de trésorerie liés aux activités de financement994.98 M1.25 B425.75 M172.13 M294.16 M-305.19 M-333.56 MFlux de trésorerie disponible-614.96 M-641.69 M-541.27 M104.16 M-8.31 M465.38 M641.34 M
Alnylam Pharmaceuticals, Inc. - Common Stock
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.